Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003–2008: The Effect of the NCI Clinical Recommendation
Authors:
Open Access
- 10 March 2014
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 4, 43
Abstract
Purpose: A 2006 National Cancer Institute (NCI) clinical announcement recommended the use of combined intravenous (IV) and intraperitoneal (IP) chemotherapy over IV chemotherapy alone for women with International Federation of Gynecology and Obstetrics (FIGO) stage 3 optimally debulked ovarian cancer due to significant survival benefit demonstrated in multiple randomized clinical trials. We examined uptake of IP chemotherapy in community practice before and after this recommendation. Methods: We identified 288 women with FIGO stage 2 or greater incident ovarian cancer diagnosed from 2003 to 2008 at three integrated delivery systems in the US. Administrative health plan data were used to determine patient characteristics and receipt of IV and IP chemotherapy within 12 months of diagnosis. We compared characteristics of women receiving IV chemotherapy alone versus IP chemotherapy (with or without IV chemotherapy) and assessed temporal trends in IP chemotherapy use. Results: Overall 12.5% (n=36) of women received IP chemotherapy during the study period. IP chemotherapy use was nonexistent between 2003 and 2005. Use of IP chemotherapy occurred among 26.9% of women diagnosed in 2006 and plateaued at 20.4% of women diagnosed in 2008. IP recipients were younger (mean age 55.9 vs 63.5 years, p= Conclusions: Use of IP chemotherapy for newly diagnosed advanced stage ovarian cancer patients was uncommon in this community setting. Future research should identify potential patient, physician, and system barriers and facilitators to using IP chemotherapy in this setting.Keywords
This publication has 10 references indexed in Scilit:
- Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOsMedical Care, 2013
- Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy ExposureCancer Epidemiology, Biomarkers & Prevention, 2012
- Accuracy and Complexities of Using Automated Clinical Data for Capturing Chemotherapy AdministrationsMedical Care, 2009
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group StudyGynecologic Oncology, 2006
- Building a Research Consortium of Large Health Systems: The Cancer Research NetworkJNCI Monographs, 2005
- Building a Virtual Cancer Research OrganizationJNCI Monographs, 2005
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2001
- Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian CancerNew England Journal of Medicine, 1996